Jane Street Group LLC Decreases Stock Holdings in Akoya Biosciences, Inc. (NASDAQ:AKYA)

Jane Street Group LLC lowered its position in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 32.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,421 shares of the company’s stock after selling 14,288 shares during the period. Jane Street Group LLC owned about 0.06% of Akoya Biosciences worth $83,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in AKYA. Bank of New York Mellon Corp raised its stake in shares of Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after acquiring an additional 9,429 shares during the last quarter. Regal Investment Advisors LLC raised its position in Akoya Biosciences by 64.3% during the 2nd quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after purchasing an additional 7,340 shares during the last quarter. GSA Capital Partners LLP raised its position in Akoya Biosciences by 87.4% during the 3rd quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after purchasing an additional 144,903 shares during the last quarter. Finally, State Street Corp grew its position in shares of Akoya Biosciences by 4.2% in the 3rd quarter. State Street Corp now owns 453,296 shares of the company’s stock worth $1,233,000 after buying an additional 18,361 shares during the last quarter. Institutional investors own 79.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Canaccord Genuity Group downgraded Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday. Piper Sandler restated an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of Akoya Biosciences in a report on Tuesday, November 19th. Finally, Craig Hallum cut shares of Akoya Biosciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $7.00 to $5.00 in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.43.

Akoya Biosciences Price Performance

Shares of AKYA stock opened at $2.75 on Thursday. The business’s fifty day moving average is $2.48 and its 200 day moving average is $2.54. The company has a quick ratio of 1.85, a current ratio of 2.75 and a debt-to-equity ratio of 5.62. The stock has a market cap of $136.30 million, a price-to-earnings ratio of -2.33 and a beta of 1.18. Akoya Biosciences, Inc. has a twelve month low of $1.88 and a twelve month high of $6.31.

About Akoya Biosciences

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.